Tectonic Therapeutic (NASDAQ:TECX) Receives New Coverage from Analysts at SVB Leerink

SVB Leerink started coverage on shares of Tectonic Therapeutic (NASDAQ:TECX) in a research note released on Wednesday morning, Benzinga reports. The firm issued an outperform rating and a $49.00 price objective on the stock.

A number of other analysts have also weighed in on TECX. Piper Sandler started coverage on shares of Tectonic Therapeutic in a report on Wednesday, June 26th. They set an overweight rating and a $76.00 target price for the company. TD Cowen started coverage on shares of Tectonic Therapeutic in a report on Monday, June 24th. They set a buy rating for the company.

Tectonic Therapeutic Stock Up 3.8 %

NASDAQ TECX opened at $17.64 on Wednesday. Tectonic Therapeutic has a 12-month low of $12.12 and a 12-month high of $19.80. The stock has a market cap of $791.86 million, a price-to-earnings ratio of 25.57 and a beta of 2.63.

Tectonic Therapeutic (NASDAQ:TECX) last posted its earnings results on Thursday, May 9th. The company reported ($0.15) earnings per share for the quarter. Sell-side analysts predict that Tectonic Therapeutic will post -4.24 earnings per share for the current fiscal year.

Tectonic Therapeutic Company Profile

Avrobio, Inc is a bio-technology company. It develops step-change cell and gene therapies for the treatment of cancer and rare disease. The company operates primarily in the United States and Canada. Avrobio, Inc is based in MA, United States.